Recent Publications
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
Sabine Paternot, Eric Raspé, Clément Meiller, Maxime Tarabichi, Jean‐Baptiste Assié, Frederick Libert, Myriam Remmelink, Xavier Bisteau, Patrick Pauwels, Yuna Blum, Nolwenn Le Stang, Séverine Tabone‐Eglinger, Françoise Galateau‐Sallé, Christophe Blanquart, Jan P Van Meerbeeck, Thierry Berghmans, Didier Jean, Pierre P Roger. Molecular Oncology 2024/4 https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.13351
An Activity-Based Oxaziridine Platform for Identifying and Developing Covalent Ligands for Functional Allosteric Methionine Sites: Redox-Dependent Inhibition of Cyclin-Dependent Kinase 4
Audrey G. Reeves, Angel Gonzalez-Valero, Patrick J. Moon, Edward Miller, Katia Coulonval, Steven W. M. Crossley, Xiao Xie, Dan He, Patricia Z. Musacchio, Alec H. Christian, Jeffrey M. McKenna, Richard A. Lewis, Eric Fang, Dustin Dovala, Yipin Lu, Lynn M. McGregor, Markus Schirle, John A. Tallarico, Pierre P. Roger, F. Dean Toste, and Christopher J. Chang. ChemRxiv (April 2022) https//doi.org/10.26434/chemrxiv-2022-9p94z
Monoclonal antibodies to activated CDK4: Use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27
Coulonval, K., Vercruysse, V., Paternot, S., Pita, J.M., Corman, R., Raspé, E., Roger, P.P. Cell Cycle, 21(1) :12-32 (jan. 2022)
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition
Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Salle F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. bioRxiv (april 2022) doi: https://doi.org/10.1101/2022.04.11.487857